Safety and tolerability profile of JEMPERLI1

Graph: JEMPERLI Adverse Reactions. See important safety information below.

Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.

*Intent-to-treat population (N=104).

Includes fatigue and asthenia.

Includes anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia.

  • The most common adverse reactions (≥20%) were fatigue/asthenia, nausea, diarrhea, anemia, and constipation1
  • Serious adverse reactions occurred in 34% of patients receiving JEMPERLI, including sepsis, acute kidney injury, urinary tract infection, abdominal pain, and pyrexia in 2.9% of patients each1
  • Adverse reactions leading to discontinuation were increased transaminase levels, sepsis, bronchitis, and pneumonitis (5 patients total)1
Icon: 4.8 Percent

of patients permanently discontinued treatment due to adverse reactions1

Icon: 4.8 Percent

of patients permanently discontinued treatment due to adverse reactions1

Icon: JEMPERLI Dosing and Administration

Find out how to dose and
administer JEMPERLI.

Icon: JEMPERLI Support

Get support for
JEMPERLI at every step.

Icon: JEMPERLI Trial

Explore the pivotal trial
for JEMPERLI.